| RS1582119130 |
C2
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS1582133194 |
COL12A1
|
Health Risk |
Pathogenic |
Ullrich congenital muscular dystrophy 2, Bethlem myopathy 2 |
| RS1582139086 |
EYS
|
Health Risk |
Likely pathogenic |
— |
| RS1582139184 |
EYS
|
Health Risk |
Likely pathogenic |
Retinitis pigmentosa, Retinitis pigmentosa |
| RS1582139308 |
EYS
|
Health Risk |
Pathogenic |
Retinitis pigmentosa, Retinitis pigmentosa |
| RS1582139761 |
COL12A1
|
Health Risk |
Pathogenic |
Ullrich congenital muscular dystrophy 2, Bethlem myopathy 2 |
| RS1582139965 |
EYS
|
Health Risk |
Pathogenic |
Retinitis pigmentosa 25, Retinitis pigmentosa 25 |
| RS1582140331 |
EYS
|
Health Risk |
Pathogenic |
Retinitis pigmentosa 25, Retinitis pigmentosa 25 |
| RS1582146096 |
EYS
|
Health Risk |
Pathogenic |
Retinitis pigmentosa, Retinitis pigmentosa |
| RS1582146275 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS1582146989 |
BCKDHB
|
Health Risk |
Pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS1582154630 |
PKHD1
|
Health Risk |
Likely pathogenic |
Polycystic kidney disease 4, Autosomal recessive polycystic kidney disease |
| RS1582164609 |
PHIP
|
Health Risk |
Pathogenic |
— |
| RS1582169095 |
RUNX2
|
Health Risk |
Pathogenic |
Cleidocranial dysostosis, Cleidocranial dysostosis |
| RS1582173192 |
VARS2
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS1582175173 |
PHIP
|
Health Risk |
Likely pathogenic |
PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome |
| RS1582176424 |
EYS
|
Health Risk |
Pathogenic/Likely pathogenic |
Retinitis pigmentosa 25, Retinitis pigmentosa 25 |
| RS1582177745 |
POLR1C
|
Health Risk |
Pathogenic |
Hypomyelinating leukodystrophy 11, Hypomyelinating leukodystrophy 11 |
| RS1582179372 |
COL12A1
|
Health Risk |
Conflicting classifications of pathogenicity |
Ullrich congenital muscular dystrophy 2, Bethlem myopathy 2 |
| RS1582180665 |
PHIP
|
Health Risk |
Pathogenic |
PHIP-related disorder, PHIP-related disorder |
| RS1582181247 |
POLR1C
|
Health Risk |
Pathogenic |
Hypomyelinating leukodystrophy 11, Hypomyelinating leukodystrophy 11 |
| RS1582184344 |
POLR1C
|
Health Risk |
Pathogenic |
Hypomyelinating leukodystrophy 11, Hypomyelinating leukodystrophy 11 |
| RS1582187890 |
SKIC2
|
Health Risk |
Likely pathogenic |
Trichohepatoenteric syndrome 2, Trichohepatoenteric syndrome 2 |
| RS1582192007 |
SKIC2
|
Health Risk |
Pathogenic/Likely pathogenic |
Trichohepatoenteric syndrome 2, Trichohepatoenteric syndrome 2 |
| RS1582196903 |
COL12A1
|
Health Risk |
Pathogenic |
Ullrich congenital muscular dystrophy 2, Ullrich congenital muscular dystrophy 2 |
| RS1582206547 |
PHIP
|
Health Risk |
Likely pathogenic |
PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome, PHIP-related behavioral problems-intellectual disability-obesity-dysmorphic features syndrome |
| RS1582208315 |
COL12A1
|
Health Risk |
Likely pathogenic |
Ullrich congenital muscular dystrophy 2, Ullrich congenital muscular dystrophy 2 |
| RS1582221424 |
EYS
|
Health Risk |
Pathogenic |
Retinitis pigmentosa, Retinitis pigmentosa |
| RS1582232661 |
RUNX2
|
Health Risk |
Pathogenic/Likely pathogenic |
Inborn genetic diseases, Cleidocranial dysostosis |
| RS1582233598 |
MAP3K7
|
Health Risk |
Likely pathogenic |
— |
| RS1582233787 |
MAP3K7
|
Health Risk |
Likely pathogenic |
Cardiospondylocarpofacial syndrome, Cardiospondylocarpofacial syndrome |
| RS1582241382 |
EYS
|
Health Risk |
Likely pathogenic |
— |
| RS1582249186 |
EYS
|
Health Risk |
Pathogenic |
Retinitis pigmentosa 25, Retinitis pigmentosa 25 |
| RS1582264160 |
RARS2
|
Health Risk |
Pathogenic |
— |
| RS1582275277 |
BCKDHB
|
Health Risk |
Likely pathogenic |
Maple syrup urine disease, Maple syrup urine disease |
| RS1582297122 |
POLH
|
Health Risk |
Pathogenic |
Xeroderma pigmentosum variant type, Xeroderma pigmentosum variant type |
| RS1582298980 |
CYP21A2
|
Health Risk |
Likely pathogenic |
ADRENAL HYPERPLASIA, CONGENITAL |
| RS1582299448 |
CYP21A2
|
Health Risk |
Pathogenic |
ADRENAL HYPERPLASIA, CONGENITAL |
| RS1582300748 |
CYP21A2
|
Health Risk |
Likely pathogenic |
ADRENAL HYPERPLASIA, CONGENITAL |
| RS1582302625 |
CYP21A2
|
Health Risk |
Pathogenic |
ADRENAL HYPERPLASIA, CONGENITAL |
| RS1582302950 |
CYP21A2
|
Health Risk |
Pathogenic |
— |
| RS1582304457 |
CYP21A2
|
Health Risk |
Pathogenic |
ADRENAL HYPERPLASIA, CONGENITAL |
| RS1582304536 |
CYP21A2
|
Health Risk |
Pathogenic |
ADRENAL HYPERPLASIA, CONGENITAL |
| RS1582305275 |
CYP21A2
|
Health Risk |
Likely pathogenic |
ADRENAL HYPERPLASIA, CONGENITAL |
| RS1582307951 |
CYP21A2
|
Health Risk |
Likely pathogenic |
ADRENAL HYPERPLASIA, CONGENITAL |
| RS1582309414 |
CYP21A2
|
Health Risk |
Likely pathogenic |
ADRENAL HYPERPLASIA, CONGENITAL |
| RS1582312633 |
CYP21A2
|
Health Risk |
Pathogenic |
ADRENAL HYPERPLASIA, CONGENITAL |
| RS1582323732 |
GUCA1A;GUCA1ANB-GUCA1A
|
Health Risk |
Pathogenic/Likely pathogenic |
Cone dystrophy 3, Isolated macular dystrophy |
| RS1582337456 |
TNXB
|
Health Risk |
Likely pathogenic |
— |
| RS1582367960 |
FBXL4
|
Health Risk |
Likely pathogenic |
Mitochondrial DNA depletion syndrome 13, Mitochondrial DNA depletion syndrome 13 |
| RS1582373132 |
RSPH9
|
Health Risk |
Pathogenic |
Primary ciliary dyskinesia, Primary ciliary dyskinesia |
| RS1582373258 |
TNXB
|
Health Risk |
Conflicting classifications of pathogenicity |
Cardiovascular phenotype, Cardiovascular phenotype |
| RS1582376398 |
EYS
|
Health Risk |
Pathogenic |
Retinitis pigmentosa, Retinitis pigmentosa 25 |
| RS1582376560 |
EYS
|
Health Risk |
Pathogenic |
— |
| RS1582376609 |
EYS
|
Health Risk |
Likely pathogenic |
Retinitis pigmentosa, Retinitis pigmentosa |
| RS1582376797 |
EYS
|
Health Risk |
Likely pathogenic |
Retinitis pigmentosa 25, Retinitis pigmentosa 25 |
| RS1582392486 |
RTN4IP1
|
Health Risk |
Likely pathogenic |
Optic atrophy 10 with or without ataxia, intellectual disability |
| RS1582396088 |
OSTM1
|
Health Risk |
Pathogenic |
Autosomal recessive osteopetrosis 5, Autosomal recessive osteopetrosis 5 |
| RS1582402094 |
FBXL4
|
Health Risk |
Likely pathogenic |
Mitochondrial DNA depletion syndrome, Mitochondrial DNA depletion syndrome |
| RS1582418143 |
HACE1
|
Health Risk |
Pathogenic |
Spastic paraplegia-severe developmental delay-epilepsy syndrome, Spastic paraplegia-severe developmental delay-epilepsy syndrome |
| RS1582425360 |
FBXL4
|
Health Risk |
Pathogenic |
Mitochondrial DNA depletion syndrome 13, Mitochondrial DNA depletion syndrome 13 |
| RS1582425406 |
FBXL4
|
Health Risk |
Pathogenic |
Mitochondrial DNA depletion syndrome 13, Mitochondrial DNA depletion syndrome 13 |
| RS1582436832 |
PKHD1
|
Health Risk |
Pathogenic |
Autosomal recessive polycystic kidney disease, Autosomal recessive polycystic kidney disease |
| RS1582441455 |
PKHD1
|
Health Risk |
Likely pathogenic |
Autosomal dominant polycystic liver disease, Autosomal dominant polycystic liver disease |
| RS1582441668 |
PKHD1
|
Health Risk |
Pathogenic |
Autosomal recessive polycystic kidney disease, Autosomal recessive polycystic kidney disease |
| RS1582461023 |
NUS1
|
Health Risk |
Pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS1582461039 |
NUS1
|
Health Risk |
Pathogenic |
Inborn genetic diseases, Inborn genetic diseases |
| RS1582461235 |
NUS1
|
Health Risk |
Pathogenic |
— |
| RS1582461267 |
NUS1
|
Health Risk |
Pathogenic |
Intellectual disability, autosomal dominant 55 |
| RS1582469538 |
PKHD1
|
Health Risk |
Likely pathogenic |
Autosomal recessive polycystic kidney disease, Polycystic kidney disease 4 |
| RS1582470309 |
PKHD1
|
Health Risk |
Pathogenic |
Autosomal recessive polycystic kidney disease, Autosomal recessive polycystic kidney disease |
| RS1582477100 |
NUS1
|
Health Risk |
Likely pathogenic |
Congenital disorder of glycosylation, type IAA |
| RS1582479341 |
PKHD1
|
Health Risk |
Likely pathogenic |
Autosomal recessive polycystic kidney disease, Autosomal recessive polycystic kidney disease |
| RS1582558097 |
GJA1
|
Health Risk |
Pathogenic |
Oculodentodigital dysplasia, Oculodentodigital dysplasia |
| RS1582558514 |
GJA1
|
Health Risk |
Pathogenic |
Oculodentodigital dysplasia, GJA1-related disorder |
| RS1582558666 |
GJA1
|
Health Risk |
Pathogenic |
Oculodentodigital dysplasia, Oculodentodigital dysplasia |
| RS1582571021 |
EYS
|
Health Risk |
Pathogenic |
— |
| RS1582576986 |
RARS2
|
Health Risk |
Likely pathogenic |
Pontocerebellar hypoplasia type 6, Pontocerebellar hypoplasia type 6 |
| RS1582601669 |
SOX4
|
Health Risk |
Pathogenic/Likely pathogenic |
Coffin-Siris syndrome 10, Intellectual disability |
| RS1582601747 |
SOX4
|
Health Risk |
Pathogenic/Likely pathogenic |
Coffin-Siris syndrome 10, Intellectual disability |
| RS1582609458 |
PSMB8
|
Health Risk |
Pathogenic |
Proteosome-associated autoinflammatory syndrome, Proteosome-associated autoinflammatory syndrome |
| RS1582634064 |
IFNGR1
|
Health Risk |
Conflicting classifications of pathogenicity |
Disseminated atypical mycobacterial infection, Disseminated atypical mycobacterial infection |
| RS1582634237 |
IFNGR1
|
Health Risk |
Pathogenic |
Disseminated atypical mycobacterial infection, Disseminated atypical mycobacterial infection |
| RS1582635229 |
IFNGR1
|
Health Risk |
Pathogenic |
Immunodeficiency 27A, Immunodeficiency 27A |
| RS1582637044 |
IFNGR1
|
Health Risk |
Likely pathogenic |
Immunodeficiency 27A, Immunodeficiency 27A |
| RS1582665975 |
MTO1
|
Health Risk |
Conflicting classifications of pathogenicity |
Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency, Inborn genetic diseases |
| RS1582666067 |
MTO1
|
Health Risk |
Pathogenic |
Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency, Mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to MTO1 deficiency |
| RS1582683374 |
ZBTB24
|
Health Risk |
Pathogenic |
Immunodeficiency-centromeric instability-facial anomalies syndrome 2, Immunodeficiency-centromeric instability-facial anomalies syndrome 2 |
| RS1582697948 |
SNX14
|
Health Risk |
Likely pathogenic |
— |
| RS1582712331 |
RARS2
|
Health Risk |
Pathogenic/Likely pathogenic |
Pontocerebellar hypoplasia type 6, Pontocerebellar hypoplasia type 6 |
| RS1582724664 |
MRPL3
|
Health Risk |
Pathogenic |
Combined oxidative phosphorylation defect type 9, Combined oxidative phosphorylation defect type 9 |
| RS1582732852 |
PEX7
|
Health Risk |
Likely pathogenic |
Rhizomelic chondrodysplasia punctata type 1, Rhizomelic chondrodysplasia punctata type 1 |
| RS1582744649 |
PEX7
|
Health Risk |
Likely pathogenic |
Peroxisome biogenesis disorder 9B, Peroxisome biogenesis disorder 9B |
| RS1582753394 |
EYS
|
Health Risk |
Pathogenic |
— |
| RS1582757650 |
PEX7
|
Health Risk |
Likely pathogenic |
Rhizomelic chondrodysplasia punctata type 1, Peroxisome biogenesis disorder 9B |
| RS1582759492 |
PRPH2
|
Health Risk |
Conflicting classifications of pathogenicity |
Macular dystrophy, PRPH2-related disorder |
| RS1582759785 |
PRPH2
|
Health Risk |
Pathogenic |
Patterned macular dystrophy 1, PRPH2-related disorder |
| RS1582760004 |
PEX7
|
Health Risk |
Likely pathogenic |
Rhizomelic chondrodysplasia punctata type 1, Rhizomelic chondrodysplasia punctata type 1 |
| RS1582764504 |
PRPH2
|
Health Risk |
Pathogenic/Likely pathogenic |
Macular dystrophy, Macular dystrophy |
| RS1582764519 |
PRPH2
|
Health Risk |
Conflicting classifications of pathogenicity |
Retinitis pigmentosa, Retinal dystrophy |